Page 28 - FLIPBOOK

CV morbidity in a randomized trial comparing LHRH-agonist and GnRH-antagonist

among patients with advanced PCa and pre-existing CV disease.

▪ Phase-II randomized open-label study among 80

men with PCa and pre-existing CVD randomized to 14
13
receive GnRH-agonists or antagonists for 1 year. Agonist Antagonist
12

Agonist Antagonist 10
(n=39) (n=41)
8
8
Myocardial infarction within 1 year 15 (38%) 15 (37%)
n
prior to randomization, N (%) 6

Cerebrovascular condition, N (%) 8 (21%) 6 (15%)
4

2
Ischemic heart disease, N (%) 26 (67%) 27 (66%) 2
1

Peripheral vascular disease, N (%) 2 (5%) 4 (10%) 0
CV Event MACCE

Margel D et al J Urol. J Urol. 2019 202(6):1199-1208. .
▪ Cardiovascular-related (CV) events include death, MI, CVA, Transient Ischemic Attack, heart catheterization with or without
intervention and cardiac related hospitalizations.
▪ Major CV and cerebrovascular events (MACCE) include death, MI, CVA and heart catheterization with stent.